AIGH Capital Management LLC Buys 649,495 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

AIGH Capital Management LLC increased its position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 82.4% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,438,109 shares of the company's stock after buying an additional 649,495 shares during the quarter. Zevra Therapeutics comprises 4.5% of AIGH Capital Management LLC's investment portfolio, making the stock its 6th biggest holding. AIGH Capital Management LLC owned about 2.63% of Zevra Therapeutics worth $10,771,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets purchased a new position in Zevra Therapeutics during the 4th quarter worth approximately $53,000. GAMMA Investing LLC boosted its position in shares of Zevra Therapeutics by 20,564.1% during the 1st quarter. GAMMA Investing LLC now owns 8,059 shares of the company's stock worth $60,000 after purchasing an additional 8,020 shares in the last quarter. Squarepoint Ops LLC boosted its position in shares of Zevra Therapeutics by 36.1% during the 4th quarter. Squarepoint Ops LLC now owns 16,534 shares of the company's stock worth $138,000 after purchasing an additional 4,384 shares in the last quarter. ProShare Advisors LLC acquired a new stake in shares of Zevra Therapeutics in the fourth quarter valued at about $145,000. Finally, Invesco Ltd. lifted its stake in shares of Zevra Therapeutics by 19.6% in the fourth quarter. Invesco Ltd. now owns 18,384 shares of the company's stock valued at $153,000 after purchasing an additional 3,007 shares during the period. Hedge funds and other institutional investors own 35.03% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ZVRA. Citigroup reaffirmed an "outperform" rating on shares of Zevra Therapeutics in a report on Wednesday, May 14th. Cantor Fitzgerald raised their price target on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the company an "overweight" rating in a report on Thursday, July 10th. Wall Street Zen lowered shares of Zevra Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Sunday, July 20th. Finally, HC Wainwright started coverage on Zevra Therapeutics in a report on Wednesday, July 2nd. They issued a "buy" rating and a $26.00 price target for the company. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $23.71.

Zevra Therapeutics Price Performance

ZVRA traded down $0.55 during trading on Friday, hitting $11.12. The company's stock had a trading volume of 590,946 shares, compared to its average volume of 623,883. Zevra Therapeutics, Inc. has a 12 month low of $5.45 and a 12 month high of $13.16. The company has a quick ratio of 2.93, a current ratio of 3.02 and a debt-to-equity ratio of 1.46. The firm's 50 day moving average price is $9.83 and its two-hundred day moving average price is $8.44. The stock has a market capitalization of $607.88 million, a price-to-earnings ratio of -5.85 and a beta of 1.97.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.15. The firm had revenue of $20.40 million during the quarter, compared to the consensus estimate of $16.96 million. Zevra Therapeutics had a negative return on equity of 201.05% and a negative net margin of 226.78%. During the same quarter in the prior year, the firm posted ($0.40) EPS. Sell-side analysts forecast that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.